Show simple item record

dc.contributor.authorSinn, M.
dc.contributor.authorNicolaou, Anna
dc.contributor.authorGebauer, B.
dc.contributor.authorPodrabsky, P.
dc.contributor.authorSeehofer, D.
dc.contributor.authorRicke, J.
dc.contributor.authorDörken, B.
dc.contributor.authorRiess, H.
dc.contributor.authorHildebrandt, B.
dc.date.accessioned2015-06-15T14:13:47Z
dc.date.available2015-06-15T14:13:47Z
dc.date.issued2013-08
dc.identifier.citationSinn M, Nicolaou A, Gebauer B, Podrabsky P, Seehofer D, Ricke J, Dörken B, Riess H and Hildebrandt B (2013) Hepatic Arterial Infusion with Oxaliplatin and 5-FU/Folinic Acid for Advanced Biliary Tract Cancer: A Phase II Study. Digestive Diseases and Sciences 58 (8): 2399-2405.en_US
dc.identifier.urihttp://hdl.handle.net/10454/7248
dc.description.abstractBackground Effective and tolerable chemotherapy with gemcitabine and cisplatin for advanced biliary tract cancer (BTC) has been established recently. However, overall prognosis is still poor, and additional therapeutic approaches are needed for patients with locally advanced, irresectable and/or pretreated tumors. Hepatic arterial infusion (HAI) of chemotherapy represents a safe and well-established treatment modality, but data on its use in patients with BTC are still sparse. Methods Patients with irresectable BTC predominant to the liver were included in a prospective, open phase II study investigating HAI provided through interventionally implanted port catheters. Intraarterial chemotherapy consisted of biweekly oxaliplatin (O) 85 mg/m2 and folinic acid (F) 170 mg/m2 with 5-FU (F) 600 mg/m2. Results Between 2004 and 2010, 37 patients were enrolled. A total of 432 cycles of HAI were applied with a median of 9 (range 1–46) cycles. Objective response rate was 16 %, and tumor control was achieved in 24 of 37 (65 %) patients. Median progression-free survival was 6.5 months (range 0.5–26.0; 95 % CI 4.3–8.7), median overall survival was 13.5 (range 0.9–50.7; 95 % CI 11.1–15.9) months. The most frequent adverse event was sensory neuropathy grade 1/2 in 10/14 patients. Conclusions Using a minimal invasive technique, repetitive HAI with OFF is feasible and results in clinically relevant tumor control with low toxicity in patients with liver predominant advanced BTC.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttp://dx.doi.org/10.1007/s10620-013-2624-yen_US
dc.subjectHepatic arterial infusion (HAI); Oxaliplatin; 5-FU/Folinic Acid; Advanced biliary tract canceren_US
dc.titleHepatic Arterial Infusion with Oxaliplatin and 5-FU/Folinic Acid for Advanced Biliary Tract Cancer: A Phase II Study.en_US
dc.status.refereedyesen_US
dc.typeArticleen_US
dc.type.versionNo full-text available in the repositoryen_US


This item appears in the following Collection(s)

Show simple item record